CN115361945A - 药物组合及其用途 - Google Patents

药物组合及其用途 Download PDF

Info

Publication number
CN115361945A
CN115361945A CN202180023639.XA CN202180023639A CN115361945A CN 115361945 A CN115361945 A CN 115361945A CN 202180023639 A CN202180023639 A CN 202180023639A CN 115361945 A CN115361945 A CN 115361945A
Authority
CN
China
Prior art keywords
inhibitor
ascorbic acid
derivative
therapeutic agent
signaling pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180023639.XA
Other languages
English (en)
Inventor
许诺
林坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Original Assignee
Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Yangshengtang Institute of Natural Medication Co Ltd filed Critical Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Publication of CN115361945A publication Critical patent/CN115361945A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本申请涉及一种药物组合，其包含：a)预防和/或治疗有效量的抗坏血酸或其衍生物；以及b)预防和/或治疗有效量的选自下组的第二治疗剂：Notch信号通路抑制剂，HH信号通路抑制剂，Porcupine抑制剂，RXRα抑制剂，Niclosamide，CK1a抑制剂和Frizzled受体抑制剂。

Description

PCT国内申请，说明书已公开。

Claims (85)

  1. PCT国内申请，权利要求书已公开。
CN202180023639.XA 2020-03-31 2021-03-30 药物组合及其用途 Pending CN115361945A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010245573 2020-03-31
CN2020102455736 2020-03-31
PCT/CN2021/084008 WO2021197333A1 (zh) 2020-03-31 2021-03-30 药物组合及其用途

Publications (1)

Publication Number Publication Date
CN115361945A true CN115361945A (zh) 2022-11-18

Family

ID=77926960

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180023639.XA Pending CN115361945A (zh) 2020-03-31 2021-03-30 药物组合及其用途

Country Status (4)

Country Link
US (1) US20230130144A1 (zh)
EP (1) EP4129283A4 (zh)
CN (1) CN115361945A (zh)
WO (1) WO2021197333A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115427032A (zh) * 2020-03-31 2022-12-02 浙江养生堂天然药物研究所有限公司 药物组合及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0398484B1 (en) 1989-05-19 1995-05-31 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Alpha-glycosyl-L-ascorbic acid, and its preparation and uses
US5078989A (en) 1990-03-28 1992-01-07 Sunstar K.K. Skin whitening cosmetics
KR20040071764A (ko) 2001-12-28 2004-08-12 산또리 가부시키가이샤 ２―Ｏ―（β―Ｄ―글루코피라노실）아스코르브산, 그의제조, 및 이를 함유하는 조성물 포함 식품 및 화장품
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma
EP2606884A1 (en) * 2011-12-21 2013-06-26 Ecole Polytechnique Fédérale de Lausanne (EPFL) Inhibitors of notch signaling pathway and use thereof in treatment of cancers
GB201318126D0 (en) * 2013-10-14 2013-11-27 Univ Cardiff Neuronal Stem Cell Differentiation
US20170304369A1 (en) * 2014-10-08 2017-10-26 Agency For Science, Technology And Research Methods of differentiating stem cells into liver cell lineages
JP2018517666A (ja) * 2015-04-06 2018-07-05 シンセン ハイタイド バイオファーマシューティカル リミテッド ウルソデオキシコール酸、ベルベリンまたはｌ−カルニチンのコンジュゲート化合物、ならびにその組成物および方法
CA3060510A1 (en) * 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US20210215702A1 (en) * 2018-06-01 2021-07-15 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
AR115493A1 (es) * 2018-06-06 2021-01-27 Ic Medtech Corp Ácido ascórbico y compuestos quinona en combinación con un agente antiparasitario para tratar enfermedades parasitarias
CN110923191B (zh) * 2018-11-23 2022-09-16 中国科学院动物研究所 将干细胞诱导为肝细胞的方法和试剂盒

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
REBECCA A等: "molecular pathways translational and therapeutic implications of the notch signaling pathway in cancer", CLIN CANCER RES., vol. 21, no. 5, 1 March 2015 (2015-03-01), pages 4 - 5, XP055854642, DOI: 10.1158/1078-0432.CCR-14-0809 *
张科生: "大剂量抗坏血酸静脉滴注治疗恶性肿瘤的进展", 医学与哲学, vol. 34, no. 6, 30 June 2013 (2013-06-30), pages 70 *
钱燕春等: "维生素C防治肿瘤作用的研究进展", 右江医学, vol. 36, no. 6, 31 December 2008 (2008-12-31), pages 27 - 29 *
陈虎等: "γ-分泌酶抑制剂对骨肉瘤细胞的作用", 中华实验外科杂志, vol. 31, no. 4, 30 April 2014 (2014-04-30) *

Also Published As

Publication number Publication date
WO2021197333A1 (zh) 2021-10-07
EP4129283A4 (en) 2024-04-24
US20230130144A1 (en) 2023-04-27
EP4129283A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
PT1663194E (pt) Utilizaã†o de saha para o tratamento de mesotelioma
WO2004010937A2 (en) Method of treating cancer
US8785423B2 (en) Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2726084A1 (en) Method of treating pathologic heterotopic ossification
JP2019508476A (ja) トリプルネガティブ乳癌の治療方法
US20150072988A1 (en) Use of n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in combination with histone deacetylase inhibitors for treatment of cancer
CN115361945A (zh) 药物组合及其用途
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
US20230338345A1 (en) Drug combination and use thereof
JP2016515625A (ja) 増殖性疾患を治療するための併用療法
JP2019519573A (ja) がんを処置するための方法
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
US20230181524A1 (en) Pharmaceutical combination and use thereof
WO2019074116A1 (ja) Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
WO2023052406A1 (en) Treatment of subjects suffering from having cholangiocarcinoma
US20230381196A1 (en) Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for treating adenoid cystic carcinoma
US20230073499A1 (en) Compounds for use in the treatment of leukemia
US20230285347A1 (en) Preterm Labour with Prostaglandin E2 Receptor Agonists
Li Notch1 signaling plays an essential role in metabolic rewiring in chemoresistance prostate cancer
JP2023046235A (ja) 医薬組成物及びｓｔａｔ３のリン酸化阻害剤
JP2006504727A (ja) 多発性骨髄腫の処置のためのラクトン誘導体
TWI839690B (zh) 治療黑色素瘤的藥物組合的用途
WO2022051388A2 (en) Quinolin-2(1h)-one inhibitors of late sv40 factor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination